2023 - Research.com Medicine in Canada Leader Award
John W. Eikelboom mostly deals with Internal medicine, Stroke, Surgery, Anesthesia and Warfarin. John W. Eikelboom regularly ties together related areas like Cardiology in his Internal medicine studies. His Stroke research is multidisciplinary, incorporating elements of Embolism, Anticoagulant, Proportional hazards model, Atrial fibrillation and Apixaban.
As a part of the same scientific study, John W. Eikelboom usually deals with the Anticoagulant, concentrating on Intensive care medicine and frequently concerns with Heparin. His Anesthesia research is multidisciplinary, relying on both Platelet aggregation inhibitor, Vascular surgery and Randomized controlled trial. John W. Eikelboom studies Dabigatran which is a part of Warfarin.
His primary areas of investigation include Internal medicine, Cardiology, Stroke, Atrial fibrillation and Surgery. His study in the field of Aspirin, Myocardial infarction, Randomized controlled trial and Rivaroxaban is also linked to topics like In patient. His Stroke study incorporates themes from Homocysteine, Vascular disease, Embolism and Risk factor.
In his study, which falls under the umbrella issue of Atrial fibrillation, Antithrombotic is strongly linked to Intensive care medicine. His biological study focuses on Dabigatran. John W. Eikelboom has researched Dabigatran in several fields, including Anticoagulant, Anesthesia and Renal function.
John W. Eikelboom spends much of his time researching Internal medicine, Aspirin, Rivaroxaban, Stroke and Atrial fibrillation. His Myocardial infarction, Coronary artery disease and Randomized controlled trial study in the realm of Internal medicine connects with subjects such as In patient. His research in Randomized controlled trial focuses on subjects like Placebo, which are connected to Anesthesia.
His Aspirin study integrates concerns from other disciplines, such as Hazard ratio, Disease, Randomization and Antithrombotic. His Antithrombotic research integrates issues from Clopidogrel, Clinical trial and Intensive care medicine. John W. Eikelboom has included themes like MEDLINE and Confidence interval in his Stroke study.
His primary areas of investigation include Internal medicine, Aspirin, Rivaroxaban, Cardiology and In patient. Internal medicine is represented through his Coronary artery disease, Randomized controlled trial, Hazard ratio, Stroke and Atrial fibrillation research. As a part of the same scientific family, John W. Eikelboom mostly works in the field of Stroke, focusing on Physical therapy and, on occasion, Stent.
His research on Atrial fibrillation focuses in particular on Warfarin. He combines subjects such as Clinical trial, Conventional PCI, Myocardial infarction, Antithrombotic and Secondary prevention with his study of Aspirin. His biological study spans a wide range of topics, including Surgery and Dabigatran, Edoxaban.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly;Michael D. Ezekowitz;John Eikelboom;Jonas Oldgren.
The New England Journal of Medicine (2009)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
Roxana Mehran;Sunil V. Rao;Deepak L. Bhatt;C. Michael Gibson.
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly;John Eikelboom;Campbell Joyner;Hans-Christoph Diener.
The New England Journal of Medicine (2011)
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli;Mahesh V. Madhavan;David Jimenez;Taylor Chuich.
Journal of the American College of Cardiology (2020)
Idarucizumab for Dabigatran Reversal
Charles V. Pollack;Paul A. Reilly;John Eikelboom;Stephan Glund.
The New England Journal of Medicine (2015)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom;Stuart J. Connolly;Jackie Bosch;Gilles R. Dagenais.
The New England Journal of Medicine (2017)
Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
John W. Eikelboom;Shamir R. Mehta;Sonia S. Anand;Changchun Xie.
Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events
John W. Eikelboom;Jack Hirsh;Jeffrey I. Weitz;Marilyn Johnston.
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
John W. Eikelboom;Lars Wallentin;Stuart J. Connolly;Mike Ezekowitz.
Homocysteine and vascular disease.
G J Hankey;J W Eikelboom.
The Lancet (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: